scholarly journals Etiologic heterogeneity of clear‐cell and papillary renal cell carcinoma in the Netherlands Cohort Study

2020 ◽  
Vol 148 (1) ◽  
pp. 67-76
Author(s):  
Jeroen A. A. Pol ◽  
Lisa George ◽  
Piet A. Brandt ◽  
Marcella M. L. L. Baldewijns ◽  
Leo J. Schouten
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Fei Meng ◽  
Luojin Zhang ◽  
Mingjun Zhang ◽  
Kaiqin Ye ◽  
Wei Guo ◽  
...  

Abstract Background BCL2L13 belongs to the BCL2 super family, with its protein product exhibits capacity of apoptosis-mediating in diversified cell lines. Previous studies have shown that BCL2L13 has functional consequence in several tumor types, including ALL and GBM, however, its function in kidney cancer remains as yet unclearly. Methods Multiple web-based portals were employed to analyze the effect of BCL2L13 in kidney cancer using the data from TCGA database. Functional enrichment analysis and hubs of BCL2L13 co-expressed genes in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) were carried out on Cytoscape. Evaluation of BCL2L13 protein level was accomplished through immunohistochemistry on paraffin embedded renal cancer tissue sections. Western blotting and flow cytometry were implemented to further analyze the pro-apoptotic function of BCL2L13 in ccRCC cell line 786-0. Results BCL2L13 expression is significantly decreased in ccRCC and pRCC patients, however, mutations and copy number alterations are rarely observed. The poor prognosis of ccRCC that derived from down-regulated BCL2L13 is independent of patients’ gender or tumor grade. Furthermore, BCL2L13 only weakly correlates with the genes that mutated in kidney cancer or the genes that associated with inherited kidney cancer predisposing syndrome, while actively correlates with SLC25A4. As a downstream effector of BCL2L13 in its pro-apoptotic pathway, SLC25A4 is found as one of the hub genes that involved in the physiological function of BCL2L13 in kidney cancer tissues. Conclusions Down-regulation of BCL2L13 renders poor prognosis in ccRCC and pRCC. This disadvantageous factor is independent of any well-known kidney cancer related genes, so BCL2L13 can be used as an effective indicator for prognostic evaluation of renal cell carcinoma.


2021 ◽  
Author(s):  
Sofia Canete-Portillo ◽  
Maria del Carmen Rodriguez Pena ◽  
Dezhi Wang ◽  
Diego F. Sanchez ◽  
George J. Netto ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 239-239
Author(s):  
Borje Ljungberg ◽  
Jan Jacobsen ◽  
Stina Häggström Rudolfsson ◽  
Gudrun Lindh ◽  
Kjell Grankvist ◽  
...  

2011 ◽  
Vol 7 (6) ◽  
pp. 261-268 ◽  
Author(s):  
S.G.C. Kroeze ◽  
A.M. Bijenhof ◽  
J.L.H.R. Bosch ◽  
J.J.M. Jans

Sign in / Sign up

Export Citation Format

Share Document